← Leaderboards
Xue-Feng Bai
Ohio State University
$4,770,529
Attributed
$4,945,385
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $781K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,945,385 · 7
By mechanism
R01$3,818,017 · 3
R21$971,535 · 3
R03$155,833 · 1
Top collaborators
- Sujit Basu1 shared
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteCancer ImmunotherapyCellsTumorMalignant NeoplasmsMediatingBaseImmunotherapyReceptorResponseCancer TherapyGrowthIn VivoRegulatory T-LymphocyteTumor MicroenvironmentProductionTumor GrowthAntigensTumor ImmunityInterleukin-10AntibodiesMelanomaCancer CellPathway Interactions
Grant awards (20)
IL-27 as a potential immunotherapeutic for cancer$349,713
R01 · FY2022 · CA
CD200R signaling in tumor growth, immunity and immunotherapy$356,850
R01 · FY2021 · CA · contact PI
IL-27 as a potential immunotherapeutic for cancer$356,850
R01 · FY2021 · CA · contact PI
CD200R signaling in tumor growth, immunity and immunotherapy$356,850
R01 · FY2020 · CA · contact PI
IL-27 as a potential immunotherapeutic for cancer$356,850
R01 · FY2020 · CA · contact PI
IL-27 as a potential immunotherapeutic for cancer$356,850
R01 · FY2019 · CA · contact PI
CD200R signaling in tumor growth, immunity and immunotherapy$346,144
R01 · FY2019 · CA · contact PI
Myeloid-derived suppressor cells in IL-27-mediated anti-tumor immunity$78,000
R03 · FY2019 · CA · contact PI
CD200R signaling in tumor growth, immunity and immunotherapy$356,850
R01 · FY2018 · CA · contact PI
Myeloid-derived suppressor cells in IL-27-mediated anti-tumor immunity$77,833
R03 · FY2018 · CA · contact PI
IL-27-based cancer vaccination approach for cancer immunotherapy$200,970
R21 · FY2016 · CA · contact PI
IL-27-based cancer vaccination approach for cancer immunotherapy$167,475
R21 · FY2015 · CA · contact PI
The role of CD200 in T cell therapy of cancer$241,530
R01 · FY2012 · CA · contact PI
The role of CD200 in T cell therapy of cancer$241,530
R01 · FY2011 · CA · contact PI
The role of CD200 in T cell therapy of cancer$249,000
R01 · FY2010 · CA · contact PI
The role of CD200 in T cell therapy of cancer$249,000
R01 · FY2009 · CA · contact PI
CD24 and thymic generation of myelin antigen specific T cells$187,500
R21 · FY2009 · AI · contact PI
CD24 and thymic generation of myelin antigen specific T cells$225,000
R21 · FY2008 · AI · contact PI
Targeting AID to Overcome Antigenic Drift$94,162
R21 · FY2006 · CA · contact PI
Targeting AID to Overcome Antigenic Drift$96,428
R21 · FY2005 · CA